30d
Early contact
Often the least distant interval, but still dependent on who answered and what was asked.
Evidence-first follow-up reading
Long‑Term Case Series
A practical synthesis for people comparing published and grey-literature follow-up cases after ibogaine exposure: what was measured, when participants were reached, and what the record cannot establish.
Follow-up duration is not the same thing as follow-up quality.
A time-based record
What a follow-up case series can show
Published accounts and grey-literature reports can describe a defined group after a treatment episode, but they vary sharply in recruitment, documentation, retention, and verification. The broader long-term outcomes overview provides context for reading these accounts without treating them as proof of effectiveness.
3–12m
Later follow-up
Useful only when the denominator, attempts to reach participants, and missing cases are stated.
Years
Multi-year reports
Potentially informative narratives, yet especially exposed to selection, recall, and survivor bias.
Compare like with like
The details that change interpretation
A useful case-series reading starts with the population and setting. Medical supervision and retreat settings may involve different screening, monitoring, support, and reporting practices. Product labels also matter: ibogaine HCl, root bark, and total alkaloid preparations should not be collapsed into one exposure description.
Sample and retention
Record the enrolled sample, the number reached at each interval, and the people missing from the final account.
Dose and repetition
Separate single-session reports from repeated dosing, and note when dose details are absent.
Outcome measure
Distinguish self-report from urine or toxicology screens, records review, mortality data, and unverified narrative.
Adverse-event record
Look for what was monitored, what was reported later, and whether cardiac outcomes were described.
A practical hierarchy
Strongest and weakest follow-up patterns
This table-like guide ranks design features, not outcomes. A longer interval is valuable only if the sample, retention, outcome method, and safety record remain visible. The interpretive questions guide helps separate a reported change from a conclusion about cause.
- Stronger Defined enrolled cohort; clear medical or retreat setting; product and single versus repeated dosing described; retention reported at 30 days, 3 months, 6 months, 12 months, or later; self-report separated from objective checks; adverse events and cardiac monitoring methods specified.
- Useful, limited Named follow-up interval and sample size, with some participant accounts, but incomplete contact attempts, unclear missing data, or outcome measures relying mainly on retrospective self-report.
- Weak Selected success stories, unspecified denominator, no attrition accounting, unclear product or dose, and no stated method for checking later outcomes or deaths.
- Not comparable Reports that combine different products, settings, dose schedules, and follow-up windows without separating them cannot support a clean comparison across cases.
Selection bias, loss to follow-up, changes in housing or care, concurrent treatment, and other life events remain possible explanations for later reports in every uncontrolled case series.
Safety belongs in the record
Cardiac outcomes, mortality, and confounders
Follow-up summaries should not focus only on self-reported substance use. They should state whether mortality was checked, whether urine or toxicology screens were used, and how adverse events were captured. Cardiac context is particularly important because ibogaine has been associated with QT interval concerns; the FDA discussion of QT prolongation and abnormal rhythms illustrates why cardiac risk reporting requires specificity rather than reassurance.
How should self-report be read?
Self-report can document what respondents say happened, but it is not interchangeable with a biologic screen or external record. A study should identify the measure and the number of respondents behind it.
What is attrition?
Attrition is loss of participants from a study over time. The standard description of attrition in clinical trials is relevant here: when participants are not reached, the later sample may no longer represent everyone who began.
Why name confounders?
Later outcomes can coincide with aftercare, psychotherapy, medication changes, other treatment, social support, employment, housing, or changes in exposure. These factors require careful handling rather than assumption.
What does “case series” mean?
A case series generally describes observations from a group without the comparison structure needed to establish causation. It can generate questions while leaving major uncertainty intact.
A careful reading practice
Use duration, detail, and missingness together
When comparing long-term ibogaine follow-up cases, keep the denominator in view: who entered, who remained reachable, what was measured, and what cannot be known from an uncontrolled account. For practical context on the decision environment, see ibogaine treatment-setting considerations.
Review aftercare & confounders